Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

NCT03386474 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Brolucizumab 6 mg
DRUG: Aflibercept 2 mg

Sponsor

Novartis Pharmaceuticals